Review Article
Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder
Table 1
Antioxidant effects of antidepressant agents: preclinical and clinical studies.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MAOI: monoamine oxidase inhibitor; NaSSA: noradrenergic and specific serotonergic antidepressant; NDRI: norepinephrine-dopamine reuptake inhibitor; NRI: norepinephrine reuptake inhibitor; SARI: serotonin antagonist and reuptake inhibitor; SNDRI: serotonin-norepinephrine-dopamine reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRE: selective serotonin reuptake enhancer; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic or tetracyclic antidepressant. |